Fractyl Health

30 articles about Fractyl Health

• Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress

  5/9/2023

  Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva ® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress.

• Fractyl Health to Present Scientific Updates on Revita® and Rejuva® Programs at Upcoming Medical Congresses

  5/2/2023

  Fractyl Health announced today that it will be presenting updates on its Revita ® and Rejuva ® programs at several upcoming medical congresses in May 2023.

• Fractyl Health Announces the Initiation of a Global Registry Study of the Revita System™ in Patients With Inadequately Controlled Type 2 Diabetes (T2D)

  4/24/2023

  Fractyl Health today announces the initiation of its Revita® Global Registry Program in Germany.

• Fractyl Health Announces Commercial Availability of Revita® in Germany and Successful First Procedure at 25th Düsseldorf International Endoscopy Symposium

  2/7/2023

  Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes, announced the commercial availability of its Revita DMR System™ in Germany.

• Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes 

  5/22/2022

  Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes, announced new data from its Revita-1 and Revita-2 studies.

• Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022

  5/17/2022

  Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes, will share new data in an oral presentation during the 2022 Digestive Disease Week meeting being held May 21-24, 2022, in San Diego, CA.

• Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR® Therapeutic Procedure in Patients with Type 2 Diabetes

  2/1/2022

  Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes, announced the publication of two-year durability data from its REVITA-1 clinical study conducted at centers in Europe and South America.

• Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di

  1/18/2022

  REVITA-T2Di is an open-label cohort evaluating Revita DMR ® in patients with insulin-treated type 2 diabetes.

• Fractyl Health Appoints Kelly Barnes to the Company’s Board of Directors

  1/12/2022

  Fractyl Health today announced the appointment of Kelly Barnes to the company’s board of directors.

• Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism

  10/27/2021

  Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes, announced the publication of an innovative new model of metabolism, the Metabolic Balance Model.

• Fractyl Announces Closing of $100 Million Series F Financing to Expand Clinical Development Programs in Type 2 Diabetes

  6/16/2021

  Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, announced the closing of a $100 million Series F financing.

• Fractyl Announces FDA Breakthrough Device Designation for Revita® DMR in Insulin-Treated Type 2 Diabetes

  4/27/2021

  Fractyl Announces FDA Breakthrough Device Designation for Revita ® DMR in Insulin-Treated Type 2 Diabetes - REVITA-T2Di study is underway to evaluate the effectiveness of Revita DMR in improving glucose control while reducing or eliminating the need for insulin -

• 

  Clinical Catch-Up: February 1 – February 5

  2/8/2021

  It was a busy week for clinical trial updates. Here’s a look.

• Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated

  2/1/2021

  - Revita ® DMR, combined with GLP-1RA medication, enables 53% of patients with type 2 diabetes to discontinue and remain off insulin for 18 months - - Results are published in peer-reviewed journal Gastrointestinal Endoscopy -

• Fractyl Raises $55 Million in Series E Financing to Advance Revita DMR for Type 2 Diabetes

  8/6/2020

  Revita® DMR is the first and only procedural therapy for type 2 diabetes; Revita DMR has been shown to durably improve blood sugar control without the need for escalating drug therapy and to reduce liver fat in NAFLD/NASH in clinical studies to date.

• Fractyl Announces FDA IDE Approval to Begin Pivotal Study of Revita DMR for Insulin-Treated Patients with Type 2 Diabetes

  6/3/2020

  Fractyl Laboratories Inc. ( Fractyl ) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) to begin a pi

• 

  Clinical Catch-Up: March 30 – April 3

  4/6/2020

  This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.

• Fractyl Announces Positive Topline Results in the Revita-2 Clinical Trial in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

  9/9/2019

  Successful completion of Fractyl’s first sham-controlled, multicenter clinical trial of Revita DMR to support EU commercial launch and inform U.S. pivotal clinical trial

• Fractyl’s Revita DMR Same-Day Therapeutic Procedure Could End Daily Insulin Injections for Type 2 Diabetes Patients

  6/8/2019

  Interim clinical data to be presented at ADA 2019 show that approximately 85 percent of patients are insulin-free at six months after Revita DMR outpatient therapy

• Fractyl Announces New Clinical Data Showing Same-Day Procedure Can Benefit Both NAFLD/NASH and Type 2 Diabetes

  4/4/2019

  Minimally invasive therapy lowered hepatic fat by 36% and Hb1AC levels by 1% in patients with non-alcoholic fatty liver disease and type 2 diabetes